Recursion Pharmaceuticals (RXRX) Other Gross PP&E Adjustments: 2020-2025
Historic Other Gross PP&E Adjustments for Recursion Pharmaceuticals (RXRX) over the last 4 years, with Sep 2025 value amounting to -$47.8 million.
- Recursion Pharmaceuticals' Other Gross PP&E Adjustments fell 151.41% to -$47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.2 million, marking a year-over-year decrease of 107.47%. This contributed to the annual value of $123.1 million for FY2024, which is 32.91% up from last year.
- Recursion Pharmaceuticals' Other Gross PP&E Adjustments amounted to -$47.8 million in Q3 2025, which was up 4.99% from -$50.3 million recorded in Q2 2025.
- In the past 5 years, Recursion Pharmaceuticals' Other Gross PP&E Adjustments registered a high of $123.1 million during Q4 2024, and its lowest value of -$53.2 million during Q1 2025.
- In the last 3 years, Recursion Pharmaceuticals' Other Gross PP&E Adjustments had a median value of $88.5 million in 2023 and averaged $33.6 million.
- Per our database at Business Quant, Recursion Pharmaceuticals' Other Gross PP&E Adjustments plummeted by 386.52% in 2021 and then spiked by 4,881.81% in 2022.
- Quarterly analysis of 5 years shows Recursion Pharmaceuticals' Other Gross PP&E Adjustments stood at -$1.7 million in 2021, then soared by 4,881.81% to $82.8 million in 2022, then climbed by 11.85% to $92.6 million in 2023, then skyrocketed by 32.91% to $123.1 million in 2024, then slumped by 151.41% to -$47.8 million in 2025.
- Its last three reported values are -$47.8 million in Q3 2025, -$50.3 million for Q2 2025, and -$53.2 million during Q1 2025.